Nouryon Gains China Regulatory Nod for Plant-Based Pharma Ingredient…

Event summary

Nouryon’s Cekol® CMC-Na received approval from China’s National Medical Products Administration for use in pharmaceutical manufacturing.
The plant-based, water-soluble excipient is produced at Nouryon’s Finland facility and offers a sustainable alternative to synthetic ingredients.
Approval expands Nouryon’s global supply of pharmaceutical-grade CMC into China’s drug manufacturing market.
Cekol CMC-Na is used in tablets, syrups, coatings, eye drops, and gels for controlled drug release.

The big picture

China’s drug manufacturing market is expanding rapidly, with increasing demand for high-quality, sustainable ingredients. Nouryon’s approval positions it to compete with local and international suppliers, leveraging its existing global supply chain. The move aligns with broader industry trends toward plant-based and eco-friendly pharmaceutical formulations.

What we're watching

Market Penetration: How quickly Nouryon can capture market share in China’s competitive pharmaceutical ingredient sector.
Regulatory Compliance: Whether Nouryon can maintain compliance with China’s stringent drug manufacturing regulations.
Sustainability Trends: The pace at which plant-based excipients displace synthetic alternatives in global drug manufacturing.